SCHEMBL23332867

SCHEMBL23332867

C=C(CCNC(=O)COC1(C)CC(C#N)C1)NC(=O)COc1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.41
▸ MEN1 O00255 4/20 0.39
▸ KMT2A Q03164 4/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ ADAMTS4 O75173 1/20 0.39
▸ MMP2 P08253 1/20 0.39
▸ MMP3 P08254 1/20 0.39
▸ MMP12 P39900 1/20 0.39
▸ MMP13 P45452 1/20 0.39
▸ ADAMTS5 Q9UNA0 1/20 0.39
▸ ATF4 P18848 4/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ BCHE P06276 1/20 0.38
▸ ACHE P22303 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ NPY1R P25929 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23383871 0.86 ATF4 (0.47) KDM4EMEN1KMT2ACYP1A2CYP2C9
SCHEMBL23383721 0.85 KDM4E (0.47) KDM4EMEN1KMT2ACYP1A2CYP2C9
SCHEMBL23383771 0.84 KDM4E (0.44) KDM4EMEN1KMT2ACYP1A2CYP2C9
SCHEMBL23333256 0.82 ATF4 (0.49) KDM4EMEN1KMT2ACYP1A2CYP2C9
SCHEMBL23182908 0.81 KDM4E (0.54) KDM4EMEN1KMT2ACYP1A2CYP2C9
SCHEMBL23332725 0.80 ATF4 (0.48) KDM4EMEN1KMT2ACYP1A2CYP2C9
SCHEMBL25962498 0.80 ATF4 (0.48) KDM4EMEN1KMT2ACYP1A2CYP2C9
SCHEMBL23294602 0.80 ATF4 (0.65) MEN1KMT2AATF4
SCHEMBL21390163 0.80 ATF4 (0.65) MEN1KMT2AATF4
SCHEMBL21390160 0.80 ATF4 (0.65) MEN1KMT2AATF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210130308-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. 2021-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210130308-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 EIF2A, EIF4A2, EIF4EBP1 KDM4E 2956/4885MEN1 3212/4885KMT2A 2893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback